Top Ten "Must Attend" Breakout Sessions at the 2011 BIO International Convention
John Sterling’s picks:
TOP TEN “MUST ATTEND” BREAKOUT SESSIONS
74 - Getting Approval for Drugs in an Ever-Increasing Risk-Averse World (Track: Achieving Regulatory Approval and Compliance)
Monday, June 27
2:00 pm - 3:15 pm
- Give insight on the changing regulatory environment and critical success factors for new applications.
- Describe the challenges of a filing process from the company’s and regulator’s point of view.
- Learn how to get a cell therapy product evaluated as a drug.
77 - Talking About Your Product in the New Age: Social Media and the Internet (Track: Achieving Regulatory Approval and Compliance)
Tuesday, June 28
3:45 pm - 5:00 pm
- Understand current regulatory standards and policies related to dissemination of information outside of labeling.
- Understand current venues for disseminating product information on the Internet and through social media.
- Understand potential liability, and identify measures to avoid it.
90 - Rediscovering the Promise of Biomarkers (Track: Biomarkers)
Tuesday, June 28
8:30 am - 9:45 am
- Learn about new models for international PPPs to reduce risk and cost for biomarker research.
- Understand the regulatory challenges facing the biomarkers qualification and validation.
- Explore how to work internationally to leverage resources for biomarker research.
198 - Crossing the Financing Gap? Alternative Strategies for Funding Biomedical Technologies for the Clinic (Track: Finance)
Monday, June 27
2:00 pm - 3:15 pm
- Describe innovative strategies that leverage alternative sources of capital to enable development.
- Discuss current financing for clinically related biotechnologies, including nontraditional sources.
- Discover nondilutive NIH funding opportunities and resources that support early development.
98 - Personalized Medicine and Companion Diagnostics: The Changing Biopharma Industry Landscape (Track: Diagnostics and Personalized Medicine)
Thursday, June 30
8:30 am - 9:45 am
- Develop an understanding of the personalized medicine landscape.
- Interact with thought leaders in the industry.
- Give audience the opportunity to follow up for potential collaborative initiatives.
174 - The Effect of a More Risk Averse Environment on Licensing Deals (Track: Business Development)
Monday, June 27
2:00 pm - 3:15 pm
- Describe the current environment within licensing biopharma companies with regard to risk for in-licensed programs.
- Indicate specific risk management strategies and their implications.
- Give advice from licensees on how best to strategize with a licensing partner.
188 - The Changing BD Environment: Overcoming Our Past to Succeed in the Future (Track: Business Development)
Tuesday, June 28
2:00 pm - 3:30 pm
- Explain the dynamics (type, economics, timing, roles) driving biotech/pharma collaborations.
- Conceptualize novel approaches to biotech and pharma collaborations.
- Identify key deal showstoppers from either a historical or novel transaction approach.
110 - Improving Innovation Through the Use of Social Networks (Track: Global Innovations & Markets)
Thursday, June 30, 2011
8:30 am - 9:45 am
- Participants will appreciate how to manage risk of engaging on social networks.
- Show how open networks may help solve big problems in innovation.
- Explain strategic considerations necessary for social networking initiatives.
126 - The Vaccine Business Opportunity — Breakthrough Technologies for Preventing and Treating Disease (Track: Innovations in Vaccines)
Monday, June 27
3:45 pm - 5:00 pm
- Identifying challenges and opportunities for vaccines in preventing infection and treating cancer.
- Give the perpsective of big biotech and pharma in this field—both established and new players.
- Describe the investor perspective on vaccines and which approaches are most likely to be funded.
141 - Safer, Faster, Cheaper: Changing Process Paradigms, Platforms and Products in Biomanufacturing (Track: Manufacturing of Biologics and Drugs)
Thursday, June 30
8:30 am - 9:45 am
- Describe the paradigm shift from handcrafted to mature process technologies in biomanufacturing.
- Describe how the FDA’s initiatives have sped the adoption of process methods since 1997.
- Demonstrate how the process controls enable faster, cheaper and safer biologics.